Instrument Inactif

Communiqués InterMune Inc

Actions

US45884X1037

Recherche biotechnologique et médicale

Cours en clôture Nasdaq
- ^USD	-

04/09/14	Roche : exclut une mega-fusion, ouvert à de plus petits rachats	RE
25/08/14	Wall Street finit dans le vert, le S&P passe un cap	RE

Communiqués

02/10/14	InterMune : Announces Effective Date of Make Whole Fundamental Change and Offer to Purchase to Holders of 2.50% Senior Convertible Notes Due 2018	PU
20/09/14	InterMune : Reports Memorandum of Understanding in Connection with Consolidated Delaware Action	PR
05/09/14	InterMune : Announces Anticipated Fundamental Change for 5.00% Convertible Senior Notes Due 2015	PR
27/08/14	InterMune : Stockholders Encouraged to Contact Securities Law Firm about Takeover	PR
27/08/14	InterMune : INVESTOR ALERT – InterMune, Inc.: The Law Offices of Vincent Wong Investigates the Sale of InterMune, Inc. to Roche Holding AG	BU
26/08/14	InterMune : INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of InterMune, Inc. and Its Board of Directors In Connection With the Sale of the Company to Roche Holding AG -- ITMN	PR
26/08/14	InterMune : Ryan & Maniskas, LLP : Announces Investigation of InterMune, Inc.	PR
25/08/14	InterMune : INVESTOR ALERT - InterMune, Inc.: The Law Offices of Vincent Wong Investigates the Sale of InterMune, Inc. to Roche Holding AG - ITMN	PR
25/08/14	InterMune : Newman Ferrara LLP : Announces Investigation of InterMune, Inc.	BU
25/08/14	InterMune : INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of InterMune, Inc. and Its Board of Directors In Connection With the Sale of the Company to Roche Holding AG	BU
25/08/14	InterMune : Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of InterMune, Inc. Stockholders	BU
24/08/14	InterMune : INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of InterMune, Inc. and Its Board of Directors In Connection With the Sale of the Company to Roche Holding AG	BU
06/08/14	InterMune : Reports Second Quarter 2014 Financial Results and Business Highlights	PU
28/07/14	InterMune : to Release Second Quarter Financial Results on August 6	PR
17/07/14	InterMune : Receives FDA Breakthough Therapy Designation For Pirfenidone, An Investigational Treatment For IPF	PR
27/05/14	InterMune : Announces Resubmission Of NDA For Pirfenidone For The Treatment Of Patients With IPF	PU
21/05/14	InterMune : Announces Additional Pirfenidone Data in Idiopathic Pulmonary Fibrosis	PU
19/05/14	InterMune : Phase 3 ASCEND Study of Pirfenidone in Idiopathic Pulmonary Fibrosis Presented at American Thoracic Society (ATS) and Published in New England Journal of Medicine	PU
16/05/14	InterMune : Announces Expanded Access Program for Pirfenidone to Treat Idiopathic Pulmonary Fibrosis (IPF) in the United States	PR
12/05/14	InterMune : Announces Upcoming Data Presentations at 2014 American Thoracic Society Meeting	PU
01/05/14	InterMune : Reports First Quarter 2014 Financial Results, Clinical Development and Business Highlights	PU
23/04/14	InterMune : To Release First Quarter Financial Results On May 1	PR
14/03/14	InterMune : Announces Pricing of Public Offering of 7,500,000 Shares of Common Stock	PR
12/03/14	InterMune Inc : InterMune Announces Proposed Public Offering of Common Stock	PR
10/03/14	InterMune Inc : Cannabis & Biotech Advancers Forging Ahead - Company Contracts With One of The Oldest Marijuana Dispensaries in California	PR